Federal Supply Schedule 36F79725D0180

Award Date 9/15/25
Last Date to Order 9/14/30
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The federal contract indefinite delivery vehicle (IDV) is a $3.5 billion Federal Supply Schedule (FSS) contract awarded by the Department of Veterans Affairs VISN 12 to Astellas Pharma US, Inc., a foreign-owned pharmaceutical manufacturer. The contract is for the procurement of drugs, pharmaceuticals, and hematology-related products, primarily to support the healthcare needs of federal agencies such as the VA and Bureau of Prisons. Under this FSS contract, two Blanket Purchase Agreements...
The federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The single-award BPA, valued at $123.5 million, is designed to provide the specialty oncology medication ICLUSIG (ponatinib) to VA medical facilities through a streamlined procurement mechanism. The BPA falls under Takeda's General Services Administration...
The federal contract indefinite delivery vehicle (IDV) is a Federal Supply Schedule (FSS) contract awarded by the Veterans Integrated Service Network 12, a civilian federal agency, to Avvisto Therapeutics LLC. The contract has a ceiling value of $225,000.00 and a period of performance from September 15, 2025 to September 14, 2030. The FSS contract is for "DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS" under the 65 I B product category. The prime contractor, Avvisto...
The federal contract indefinite delivery vehicle (IDV) is a Federal Supply Schedule (FSS) contract awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Therapeuticsmd, Inc. for the provision of pharmaceuticals, drugs, and hematology-related products under the Pharmaceuticals and Drugs (FSS-61-IB) master schedule. This multiple-award contract has a potential value of $250,000.00 and a period of performance from May 15, 2020 to May 15, 2024. Therapeuticsmd, Inc.,...
The federal contract Indefinite Delivery Vehicle (IDV) award is a Federal Supply Schedule (FSS) contract with the Department of Veterans Affairs (VA) for the procurement of drugs, pharmaceuticals, and hematology-related products. The prime contractor is Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc. The contract has a total ceiling value of $290,000,000 and a period of performance through March 31, 2030. The focus of this IDV contract is the delivery of Progenics'...
The federal contract indefinite delivery vehicle (IDV) is a Federal Supply Schedule (FSS) contract awarded by the Veterans Integrated Service Network 12 (VISN 12), a civilian federal agency, to Bridgebio Pharma, Inc. The contract is for the procurement of "DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS" with a ceiling value of $250,000.00 and a period of performance from July 31, 2025 to July 30, 2030. As a multiple award FSS contract, this vehicle allows VISN 12 and other...
The federal contract indefinite delivery vehicle (IDV) award is a Federal Supply Schedule (FSS) contract for Drugs, Pharmaceuticals, & Hematology Related Products (65 I B). The contract was awarded to Revance Therapeutics, Inc. (Revance) by the Department of Veterans Affairs (VA) on May 15, 2024, with a ceiling value of $225,000.00 and a period of performance through May 14, 2029. The FSS contract vehicle allows the VA to procure pharmaceutical and drug products from Revance through task...
The federal contract IDV is a Federal Supply Schedule (FSS) contract awarded by the Department of Veterans Affairs (VA) to Nobelpharma America, LLC, a foreign-owned, self-certified small disadvantaged business. The FSS contract, under Federal Supply Class 65 I B, provides for the delivery of pharmaceutical and hematology-related products to VA facilities nationwide, with a ceiling value of $225,000 and a period of performance through May 2028. Additionally, Nobelpharma America, LLC was awarded a...
The federal contract indefinite delivery vehicle (IDV) award is a Federal Supply Schedule (FSS) contract under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, awarded to Biocon Biologics Inc. by the Veterans Integrated Service Network 12 (VISN 12), a civilian agency. The contract has a ceiling value of $750,000.00 and a period of performance from March 1, 2024 to February 28, 2029. The contract is for the delivery of "Drugs, Pharmaceuticals, & Hematology Related Products" under...
This federal contract Indefinite Delivery Vehicle (IDV) is a single-award Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc. The BPA has a ceiling value of $15,000,000 and a period of performance through September 19, 2026. The purpose of this BPA is to provide the VA with the oncology medications BALVERSA and CARVYKTI. This IDV is issued against the Pharmaceuticals...
  • 36F79725D0180
    Federal Supply Schedule
  • -
    Blanket Purchase Agreements

The federal contract indefinite delivery vehicle (IDV) is a Federal Supply Schedule (FSS) contract awarded by the U.S. Department of Veterans Affairs (VA) to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract, which falls under FSS Contract 65 I B for Drugs, Pharmaceuticals, & Hematology Related Products, has a ceiling value of $2,894,759,990 and a period of performance through September 14, 2030.

Under this IDV, Takeda Pharmaceuticals America, Inc. is the prime contractor responsible for providing a range of pharmaceutical products, particularly oncology medications, to various Veterans Integrated Service Networks (VISNs) and VA medical facilities nationwide. The company holds a significant $123.5 million Blanket Purchase Agreement (BPA) with the VA National Acquisition Center to supply the specialty oncology drug ICLUSIG (ponatinib) through streamlined delivery orders. Additionally, Takeda Pharmaceuticals America, Inc. has been awarded numerous firm-fixed-price delivery orders ranging from $13,000 to $173,000 for specific dosages of ICLUSIG, supporting the VA's mission of providing comprehensive healthcare services to veterans.

Generated 9/14/25, 12:43 AM